You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-Thymmune Therapeutics and M13 Therapeutics win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to further their research- CAMBRIDGE, Mass., Nov. 3, 2021 /
Astellas ranked again in Seramount's 100 Best Companies and Best Companies for Dads lists. NORTHBROOK, Ill., Sept. 28, 2021 /PRNewswire/ -- Seramount (formerly Working Mother Media) revealed its...
Read more about Astellas Recognized Consistently Among Top Companies for Working Parents
Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 21, 2021 /PRNewswire/ --...
Astellas' "Future Innovator Prize" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas CAMBRIDGE, Mass., Aug....
- PROGRAF Becomes First Immunosuppressive Drug Approved in the U.S. for People Receiving a Lung Transplant - NORTHBROOK, Ill., July 20, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,...
Follow U.S. news
